CTI BioPharma Corp. (NASDAQ:CTIC) Director Richard L. Love sold 14,600 shares of CTI BioPharma Corp. stock in a transaction on Friday, September 29th. The stock was sold at an average price of $3.21, for a total transaction of $46,866.00. Following the completion of the transaction, the director now directly owns 84,318 shares in the company, valued at $270,660.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

CTI BioPharma Corp. (NASDAQ CTIC) opened at 3.25 on Thursday. The firm has a 50-day moving average of $3.26 and a 200 day moving average of $3.65. CTI BioPharma Corp. has a 12-month low of $0.36 and a 12-month high of $6.48. The stock’s market capitalization is $103.11 million.

CTI BioPharma Corp. (NASDAQ:CTIC) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.63. CTI BioPharma Corp. had a negative return on equity of 418.99% and a negative net margin of 136.76%. The business had revenue of $22.23 million during the quarter. On average, analysts predict that CTI BioPharma Corp. will post ($1.26) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “CTI BioPharma Corp. (CTIC) Director Sells $46,866.00 in Stock” was first reported by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.watchlistnews.com/cti-biopharma-corp-ctic-director-sells-46866-00-in-stock/1610045.html.

Several hedge funds have recently made changes to their positions in the stock. Stonepine Capital Management LLC bought a new stake in shares of CTI BioPharma Corp. during the 2nd quarter worth $7,561,000. WASHINGTON TRUST Co bought a new stake in shares of CTI BioPharma Corp. during the 2nd quarter worth $104,000. Finally, Segantii Capital Management Ltd bought a new stake in shares of CTI BioPharma Corp. during the 1st quarter worth $102,000. Institutional investors and hedge funds own 42.87% of the company’s stock.

Separately, Jefferies Group LLC started coverage on shares of CTI BioPharma Corp. in a report on Tuesday, September 12th. They issued a “buy” rating and a $7.50 price target on the stock.

CTI BioPharma Corp. Company Profile

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.